Abstract:Background: Cancer stem cells (CSCs) are a rare population of tumor initiating cells associated with chemoresistance, recurrence and poor survival. Our group previously correlated germline variants in ovarian CSC-related genes with chemoresponse in 362 high-grade serous ovarian cancer (HGSOC) patients. Here, we evaluate CSC variants in a large, independent population to determine their association with overall (OS) and progression-free (PFS) survival.Methods: Over 2,500 women of European ancestry diagnosed with HGSOC who underwent cytoreductive surgery have been followed for clinical outcome and genotyped on the OncoArray. We identified 4,209 common (MAF>0.01) short polymorphisms (SNPs) that were genotyped or well-imputed (r2>0.70) within 26 CSC-related genes. Associations with OS and PFS were estimated with additive genetic cox proportional hazards models adjusted for ancestral principal components, age at diagnosis, and study. Residual disease after surgery (≤1cm vs. >1cm), and stage at diagnosis (advanced vs. local) were assessed for confounding (covariate), modification (interaction), and mediational (logistic regression) effects. For each SNP, the best fit model was adopted and p-values were adjusted for multiple testing using a false discovery rate (FDR) < 15% threshold. Primary analyses evaluated 1,254 patients who received standard chemotherapy; secondary analysis included 2,659 patients, regardless of chemotherapy regimen.Results: Two genes that were previously associated with response to chemotherapy (ESRRB, ALDH1A1) and two new genes (NOTCH2, CXCR4) were associated with OS and PFS. Eight variants within ESRRB were significantly associated with improved OS and comprised four independent (rsq<0.2) intronic variants. The top hit rs7160216 (HR=0.61, P=8.4x10-7, FDR=0.004) was modified by residual disease with the association attenuated in optimally debulked patients (HR=0.88, P interaction=0.05). One independent variant in ALDH1A1 was associated with an almost 2-fold lower OS (rs17563633 HR=1.80, P=7.2x10-5, FDR=0.03) and a ~6-fold lower OS in suboptimally debulked patients (HR=5.8, P interaction=9.2x10-4). Analysis of all patients, irrespective of chemotherapy, identified a significant association for rs17848385 in CXCR4 with reduced OS (HR=1.36, P=1.3x10-5, FDR=0.05). Aforementioned variants also displayed similar, significant associations with PFS though without modification. No significant SNP effects on survival were mediated through residual disease or stage; however, uncorrelated SNP blocks in ESRRB and ALDH1A1 associated with these factors proposing possible genomic interaction.Conclusion: Polymorphisms in CSC genes are associated with survival of HGSOC and more research is needed to clarify the prognostic value of these genes, particularly as carriers may benefit from emerging therapies targeting CSC pathways.Citation Format: Brett M. Reid, Jennifer B. Permuth, Zhihua Chen, Ann Chen, Thomas A. Sellers, on behalf of the Ovarian Cancer Association Consortium (OCAC). Germline polymorphisms in cancer stem cell genes associate with survival among women with high-grade serous ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1562.

Cancer Stem Cell Markers-Clinical Relevance and Prognostic Value in High-Grade Serous Ovarian Cancer (HGSOC) Based on The Cancer Genome Atlas Analysis

Abstract 1562: Germline Polymorphisms in Cancer Stem Cell Genes Associate with Survival among Women with High-Grade Serous Ovarian Cancer

Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in Ovarian Cancer Patients: Evidence from 52 Studies.

Identification Of A Potential Ovarian High-Grade Serous Cancer Stem Cell Marker And Its Clinicopathological Associations

Identification of Prognosis Biomarkers for High-Grade Serous Ovarian Cancer Based on Stemness.

Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line

Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas.

A 2-Protein Signature Predicting Clinical Outcome In High-Grade Serous Ovarian Cancer

Cancer Stem Cell Markers Are Differentially Expressed in Malignant Ovarian Germ Cell Tumors

Proteomics analysis to reveal biological pathways and predictive proteins in the survival of high-grade serous ovarian cancer

Role of cancer stem cell markers ALDH1, BCL11B, BMI-1, and CD44 in the prognosis of advanced HNSCC

Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer

Identification of Hub Genes and Compounds Controlling Ovarian Cancer Stem Cell Characteristics Via Stemness Indices Analysis.

Ovarian cancer stem cell-specific gene expression profiling and targeted drug prescreening.

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

Clinical significance of putative markers of cancer stem cells in gastric cancer: A retrospective cohort study.

T-cell activation is associated with high-grade serous ovarian cancer survival

Core Signaling Pathways in Ovarian Cancer Stem Cell Revealed by Integrative Analysis of Multi-Marker Genomics Data

Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases

Prognostic Significance of Differential Expression of Angiogenic Genes in Women with High-Grade Serous Ovarian Carcinoma

Integrated Analysis To Identify Molecular Biomarkers Of High-Grade Serous Ovarian Cancer